As most marketed anti-EGFR mAbs are targeted on Domain I/III of EGFR ECD, this may explain why the epitope has anti-tumor activity in HCC, distinguishing it from anti-EGFR antibodies and TKIs. This evidence concerns the gene EGFR and neoplasm.